IL-6 involvement in epithelial cancers - PubMed (original) (raw)

Comment

IL-6 involvement in epithelial cancers

Zachary T Schafer et al. J Clin Invest. 2007 Dec.

Abstract

In this issue of the JCI, two reports provide intriguing new information on the role of the inflammatory cytokine IL-6 in breast and lung cancer. The study by Sansone et al. implicates IL-6 in the instigation of malignant properties in breast cancer stem cells (see the related article beginning on page 3988). The study by Gao et al. identifies mutant variants of EGFR as inducers of IL-6 in lung adenocarcinomas (see the related article beginning on page 3846). These studies add to our understanding of potential roles for IL-6 in cancer and further motivate investigations of IL-6-targeted chemotherapeutics.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Models for role of IL-6 in breast and lung carcinomas.

In this issue of the JCI, Sansone et al. (6) show that the tumorigenic conversion of mammary stem cells (CD44hiCD24lo) results in an increase in IL-6 expression and secretion. IL-6 secretion results in a positive feedback loop causing further IL-6 upregulation and secretion. Once secreted, IL-6 can bind the IL-6 receptor (IL-6R), causing the upregulation of the Notch-3 ligand Jagged-1, which triggers the upregulation of CA-IX. While not depicted here, it should be noted that Jagged-1 is a transmembrane ligand. The result of these changes is the promotion of malignant features in these mammary stem cells. Also in this issue, Gao et al. (7) show that EGFR mutations in lung adenocarcinoma cells cause an increase in IL-6 expression and secretion. This, in turn, promotes malignant features in these cells through the IL-6 receptor activation–mediated phosphorylation of STAT3.

Comment on

Similar articles

Cited by

References

    1. Kishimoto T. Interleukin-6: from basic science to medicine — 40 years in immunology. Annu. Rev. Immunol. 2005;23:1–21. - PubMed
    1. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer. 2005;41:2502–2512. - PubMed
    1. Chiu J.J., Sgagias M.K., Cowan K.H. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin. Cancer Res. 1996;2:215–221. - PubMed
    1. Conze D., et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001;61:8851–8858. - PubMed
    1. Sansone P., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. . J. Clin. Invest. 2007;117:3988–4002. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources